Jefferies Financial Group Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Jefferies Financial Group Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $597,022 - $883,792	24,980 Added 124900.0%	25,000 $794,000
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $70,696 - $109,421	-3,098 Reduced 99.36%	20 $0
Q4 2022 Sep 21, 2023	SELL	$25.35 - $31.96 $554,708 - $699,348	-21,882 Reduced 87.53%	3,118 $98,000
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $79,041 - $99,651	3,118 New	3,118 $98,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.